Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Atg16 Lentiviral Activation Particles (m2): sc-429488-LAC-2
- Target species: mouse
- 200 µl of transduction-ready, high-titer CRISPR/dCas9 Lentiviral Activation Particles
- Atg16 Lentiviral Activation Particles (m2) is a synergistic activation mediator (SAM) transcription activation system designed to specifically and efficiently upregulate gene expression via lentiviral transduction of cells
- Atg16 Lentiviral Activation Particles (m2) contain the following SAM Activation elements: a deactivated Cas9 (dCas9) nuclease (D10A and N863A) fused to the transactivation domain VP64, an MS2-p65-HSF1 fusion protein and a target-specific 20 nt guide RNA. They also contain the blasticidin, hygromycin and puromycin resistance genes
- Upon transduction, the SAM complex binds to a site-specific region approximately 200-250 nt upstream of the transcriptional start site and provides robust recruitment of transcription factors for highly efficient gene activation
- gRNAs encoded by Atg16 Lentiviral Activation Plasmid (m2) and Atg16 Lentiviral Activation Plasmid (m22) target distinct regulatory regions of the Atg16l1 promoter. One or both designs may be available
- Following transfection, gene activation efficiency can be assayed by WB, IF or IHC using antibody: Atg16 Antibody (E-10): sc-393274
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Atg16 Lentiviral Activation Particles (m2) | sc-429488-LAC-2 | 200 µl | $455.00 |
Mouse Atg16l1 encodes ATG16, a core component of the ATG12–ATG5–ATG16L1 complex that specifies autophagosome formation during macroautophagy and supports LC3 lipidation at nascent phagophores. ATG16L1 coordinates selective and basal autophagy, contributing to cytoplasmic quality control, organelle turnover, and antimicrobial responses, with downstream effects on innate immune signaling and epithelial barrier homeostasis. Genetic and functional perturbation of Atg16l1 is linked to inflammatory phenotypes and intestinal pathology, making it a widely used target for modeling autophagy-associated immune dysregulation. Gene editing of Atg16l1 in mouse cells or in vivo systems enables mechanistic studies of autophagosome biogenesis, host–microbe interactions, and stress-response pathways in relevant tissues.
Atg16 Lentiviral Activation Particles (m2) address this need by packaging the complete synergistic activation mediator (SAM) transcriptional activation system into transduction-ready, high-titer lentiviral particles, enabling efficient Atg16l1 upregulation across a broader range of human cell types.
Atg16 Lentiviral Activation Particles (m2) deliver all functional components of the synergistic activation mediator (SAM) system via lentiviral transduction. The system comprises three particle preparations co-transduced into target cells: one encoding catalytically inactive dCas9 (D10A and N863A mutations) fused to the VP64 transactivation domain with a blasticidin resistance gene; one encoding the MS2-p65-HSF1 fusion protein with a hygromycin resistance gene; and one encoding a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers with a puromycin resistance gene. Following lentiviral transduction and genomic integration of the expression cassettes, the SAM components are stably expressed and assemble at the target locus within the proximal promoter region upstream of the Atg16l1 transcriptional start site, where VP64, p65, and HSF1 act cooperatively to recruit endogenous transcriptional machinery and drive sustained upregulation of endogenous Atg16 expression. The use of nuclease-inactive dCas9 avoids the introduction of double-strand DNA breaks and preserves the native Atg16l1 genomic locus and regulatory architecture.
The lentiviral format offers several practical advantages: stable genomic integration supports heritable activation across cell divisions; high-titer particle preparations eliminate the need for in-house viral production; and compatibility with primary, non-dividing, and transfection-resistant cell types expands experimental accessibility. Successful transduction can be confirmed and enriched through triple antibiotic selection using puromycin, hygromycin, and blasticidin.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.